GlobalData on MSN15d
Adaptimmune nears second sarcoma approval as Phase II trial hits endpoints
Adaptimmune’s Phase II IGNYTE-ESO trial investigating experimental T cell therapy lete-cel has achieved its primary endpoint.
Cure Today6d
T-Cell Therapy With Lete-Cel Demonstrates Efficacy in Sarcoma Subtypes
Researchers observed responses in patients with synovial sarcoma or myxoid/round cell liposarcoma treated with lete-cel.
BioSpace15d
Adaptimmune Plots Path to FDA as Sarcoma Cell Therapy Aces Pivotal Trial
Following strong treatment response data for Adaptimmune’s lete-cel, the biotech is planning to initiate a rolling BLA ...
Yahoo Finance8d
Comprehensive Synovial Sarcoma Pipeline Landscape Report for 2024: In-depth Analysis of 20+ Pipeline Drugs and 15+ Companies
Dublin, Nov. 21, 2024 (GLOBE NEWSWIRE) -- The "Synovial Sarcoma - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering A groundbreaking insight into the Synovial ...